MedTrace Logo

A Study to Compare the Safety, Tolerability, and Pharmacokinetics of CTP-692 Versus D-serine in Healthy Volunteers

NCT03778320 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2019-03-15

No results posted yet for this study

Summary

This study will assess the safety, tolerability and pharmacokinetic (PK) profile of CTP-692 vs D serine.

Conditions

  • Healthy Volunteers

Interventions

DRUG

CTP-692

Single oral dose

DRUG

D-Serine

Single oral dose

Sponsors & Collaborators

  • Concert Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Emily McIntyre · Concert Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-14
Primary Completion
2018-12-23
Completion
2019-01-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03778320 on ClinicalTrials.gov